Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06823859 PK and Safety in Healthy Chinese Participants
NCT05257798Phase 1Completed
- Sponsor
- Pfizer
- Start
- Feb 2022
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in dermatomyositis (DM), polymyositis (PM) and systemic lupus erythematosus (SLE) comparing PF-06823859 with Placebo (2 arms). Primary endpoints: Maximum Serum Concentration at Day 157, Time to Maximum Serum Concentration at Day 157 and 9 more. Started Feb 2022; status: completed.
02
Drugs
dazukibart
03
Conditions
dermatomyositis (DM)polymyositis (PM)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05257798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05257798.